AstraZeneca PLC (LON:0A4J)

Market Cap	200.04B
Revenue (ttm)	43.24B
Net Income (ttm)	6.99B
Shares Out	n/a
EPS (ttm)	4.48
PE Ratio	28.61
Forward PE	16.93
Dividend	0.88 (1.07%)
Ex-Dividend Date	Aug 8, 2025

Volume	416
Average Volume	7,451
Open	82.89
Previous Close	84.55
Day's Range	82.89 - 82.89
52-Week Range	62.79 - 84.55
Beta	0.18
RSI	62.59
Earnings Date	Nov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4J

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD